DDInter1729 DDInter108
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012.
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Apixaban
Sulindac {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Apixaban
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apixaban
Sulindac {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apixaban
Sulindac {u} (Compound) causes {v} (Side Effect) Gastrointestinal haemorrhage
Gastrointestinal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Sulindac {u} (Compound) causes {v} (Side Effect) Vaginal haemorrhage
Vaginal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Diflunisal
Diflunisal {u} may lead to a major life threatening interaction when taken with {v} Apixaban
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Sulindac {u} (Compound) binds {v} (Gene) PPARD
PPARD {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Treprostinil
Treprostinil {u} may lead to a major life threatening interaction when taken with {v} Apixaban
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Apixaban (Compound)
Sulindac (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apixaban
Sulindac (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apixaban
Sulindac (Compound) causes Gastrointestinal haemorrhage (Side Effect) and Gastrointestinal haemorrhage (Side Effect) is caused by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Sulindac (Compound) causes Vaginal haemorrhage (Side Effect) and Vaginal haemorrhage (Side Effect) is caused by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Diflunisal (Compound) and Diflunisal may lead to a major life threatening interaction when taken with Apixaban
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Rifabutin (Compound) and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Sulindac (Compound) binds PPARD (Gene) and PPARD (Gene) is bound by Treprostinil (Compound) and PPARD (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may lead to a major life threatening interaction when taken with Apixaban